NLRC5/CITA: A Key Player in Cancer Immune Surveillance
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Cancer cells need to escape immune surveillance for successful tumor growth. Loss of MHC class I has been described as a major immune evasion strategy in many cancers. MHC class I transactivator (CITA), NLRC5, has found to be a key transcription coactivator of MHC class I genes. Recent genetic studies revealed that NLRC5 is a major target for cancer immune evasion mechanism. The reduced expression or activity of NLRC5 caused by promoter methylation, copy number loss, or somatic mutations is associated with defective MHC class I expression, impaired cytotoxic T cell activation and poor patient prognosis. Here we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 5×
“anti-CTLA4, anti-PD-1/PDL1), adoptive T cells, chimeric antigen receptor (CAR)-modified T cells [83] and administration of immunostimulatory cytokines (IL-2, GM-CSF)[6, 7, 42, 84] rely on the activity of T cells.”
BackgroundInfluentialCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“To compensate this, various trials combining therapeutics are ongoing, such as anti-CTLA4 (ipilimumab) and anti-PD-1 (nivolumab) [87], vaccination and checkpoint inhibitors [88, 89], or targeted therapy (BRAF and MEK inhibitors) and checkpoint inhibitors [90].”
BackgroundCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 4×
“Cancer cells utilize multiple strategies to evade the host immune system [44–46], which include the recruitment of regulatory immune cell subsets or the induction of anergy in activated T cells [47], increased resistance to cytotoxic T-cell killing [48, 49], reduced recognition of tumor-associated antigens by effector…”
BackgroundInfluentialMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“(perforin-1) and GZMA (granzyme A), which are associated with cytotoxic T cell activity in tumors [43].”
BackgroundChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“anti-CTLA4, anti-PD-1/PDL1), adoptive T cells, chimeric antigen receptor (CAR)-modified T cells [83] and administration of immunostimulatory cytokines (IL-2, GM-CSF)[6, 7, 42, 84] rely on the activity of T cells.”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
Gao, Y., Päivinen, P., Tripathi, S., Domènech-Moreno, E., Wong, I. P. L., Vaahtomeri, K., Nagaraj, A. S., Talwelkar, S. S., Foretz, M., Verschuren, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2049 · Cited by 40
“frequently downregulated in many different cancers by enabling immune evasion (24, 25), and a recent study identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) in epigenetically modulating the regulation of NLRC5 and antigen presentation pathway including B2M (26).”
BackgroundMR1 overexpression correlates with poor clinical prognosis in glioma patients
Kubica, P., Lara-Velazquez, M., Bam, M., Siraj, S., Ong, I., Liu, P., Priya, R., Salamat, S., Brutkiewicz, R. R., & Dey, M. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab034 · Cited by 20
Computational studies on the functional and structural impact of pathogenic mutations in enzymes
Dissanayake, U. C., Roy, A., Maghsoud, Y., Polara, S., Debnath, T., & Cisneros, G. A. (2025) · Protein Science · doi:10.1002/pro.70081 · Cited by 8
Metadata
- Authors
- Yoshihama, S., Vijayan, S., Sidiq, T., & Kobayashi, K. S.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 3
- Issue
- 1
- Pages
- 28-38
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2569601970
- Cited by
- 94
- References
- 17
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.